An insider’s guide to the business, policy and science of psychedelics.

Explore

Read By

Our Plans

Basic

Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.

Learn More

	Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers
Subscribe Now Monthly $20 Annually $200

Why Pα+?

Where serious stakeholders turn for comprehensive psychedelic medicines coverage.

Pα+ is relied upon by funders, pharmaceutical companies, policymakers, practitioners, and entrepreneurs who need to follow psychedelic medicines closely and continuously. Around 80% of our reporting and analysis is published exclusively for subscribers. That means original reporting, early signals, and sustained coverage across drug development, policy, regulation, and access — designed for those who cannot afford to miss what is happening in the field.

Our Approach

We adopt a critical and
analytical point of view.

Never pessimistic or cynical, our coverage is designed to provide a unique lens on the psychedelic medicines field as it develops. We take an opinionated, analytical approach to the intersection of psychedelics and business, and we do not shy away from difficult questions or complexity. Pα+ brings together deeply researched analysis, in-the-weeds reporting, and structured explainers to help readers stay abreast of a rapidly evolving space. While our core focus is the business of psychedelics, this necessarily spans drug development, financing, science, legal frameworks, and broader cultural contexts.

The Pα Take

Our coverage often dives deep. The Pα Take distils key takeaways, analysis, and opinion throughout our reporting, helping readers quickly grasp what matters and why.

Deeply Researched

Our work is grounded in primary sources, original analysis, and our sustained tracking of clinical, regulatory, and policy developments across the world.

Explainers & Context

We produce explainers that unpack complex topics, providing historical context and practical framing for engaging with psychedelic drug development, regulation, and access.

Types of Coverage

Bulletins

Our flagship Bulletins provide one-stop coverage of developments across the psychedelics field. Published multiple times a month, they synthesise news, data, and analysis into a coherent picture of how the field is evolving, helping readers maintain continuity and perspective over time.

Deep Dives

Deep Dives explore specific topics in depth, from clinical trial readouts and regulatory frameworks to international developments. These pieces are designed to surface nuance, interrogate assumptions, and examine implications that only emerge through sustained analysis.

Breaking News

Our breaking news coverage focuses on developments that materially affect the psychedelic medicines field. We’re often the first to report on stories in the field through scoops and exclusives.

Quarterly Briefings

New for 2026, our Quarterly Video Briefings provide a structured review of the preceding quarter, followed by a forward-looking assessment. Designed for busy professionals, they offer a concise way to stay oriented on key developments and emerging trends.

Interviews

Our interviews feature in-depth conversations with researchers, executives, policymakers, and practitioners shaping the psychedelic medicines ecosystem.

Resources

Select Resources are available exclusively to Pα+ subscribers, offering up-to-date, structured views into psychedelic drug development, policy, and access.